•   
  •   
  •   

Health & Fit Closely Watched Mirati Reveals Results to Rival Amgen Drug

19:20  25 october  2020
19:20  25 october  2020 Source:   msn.com

How the Pandemic Is Making the Opioid Crisis Worse

  How the Pandemic Is Making the Opioid Crisis Worse As the covid crisis fuels a surge in overdoses, scientists race to halt addiction at its source: the brain.The need for such an intervention is more urgent than ever. Addiction has claimed 750,000 lives since 1999, according to the Centers for Disease Control. This year, COVID-19-related developments are adding to the downward spiral. Over the last three to four months overdose deaths have increased nationwide by close to 15 percent, says Shawn Ryan, Chair of Legislative Advocacy for the American Society of Addiction Medicine.

Both Mirati and Amgen ’s medicines target a mutation on a gene called KRAS found in an estimated 13% of non-small cell lung tumors. Results for one lung cancer patient whose cancer had spread to their brain showed their tumors shrank and a brain lesion disappeared. Adagrasib data in other tumor types were also presented on Sunday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, though the most promising results to date for these drugs has been seen in lung cancer.

Mirati ’s Kras inhibitor looks better than Amgen ’s on efficacy, but toxicity worries prevent a knockout punch. Conferences. In the battle of the Kras inhibitors Mirati yesterday struck a blow against its big biotech rival , Amgen . In data presented at the Triple meeting, Mirati ’s adagrasib showed a 45% overall response rate in non-small cell lung cancer, numerically better than the 35% ORR previously seen However, it might be too soon for Mirati investors to break out the bubbly: the data are not a knockout, and though Mirati has now revealed its filing plans Amgen is ahead in the race to get approval.

(Bloomberg) -- Mirati Therapeutics Inc., one of the most talked-about names in biotech and a frequenter of Wall Street’s M&A shopping lists, released drug-trial results that set a higher bar against a competitor drug from biotech behemoth Amgen Inc.

The experimental drug, known as adagrasib, or MRTX849, produced responses in 45% of lung cancer patients in an early stages of study. That’s better than some of the results from Amgen’s sotorasib. Because patients whose tumors shrank on Mirati’s drug are still in treatment, it’s too early to know how long the average response to the drug lasts -- a key metric Wall Street is watching.

The world desperately needs coronavirus treatments, even if we get a vaccine. These 9 candidates are our best hope so far.

  The world desperately needs coronavirus treatments, even if we get a vaccine. These 9 candidates are our best hope so far. Most have entered human trials, and a few have already seen positive data, but some candidates have yet to publish clinical results.Like most viruses, the novel coronavirus isn't likely to disappear from the population for good. Instead, the world's best hope is a combination of public-health measures, drug treatments, and a vaccine.

Track breaking Amgen headlines on NewsNow: the one-stop shop for Amgen news. Mirati 's KRAS drug shrinks 45% of NSCLC tumors, putting it in Amgen 's slipstream on race to FDA FierceBiotech11:37 26-Oct-20. Closely Watched Mirati Reveals Results to Rival Amgen Drug BNN Bloomberg15:28 25-Oct-20.

An experimental drug from Mirati Therapeutics Inc that targets a specific genetic mutation significantly reduced tumor size in 40% of patients with advanced lung and colorectal cancer so far evaluated in a small, early-stage trial, researchers said on Monday. Investors have been keen to see how Mirati 's data stacks up against results for a similar drug , AMG510, under development by Amgen Inc. Both target a mutated form of Investors this week will be closely watching the Federal Open Market Committee's (FOMC) Wednesday monetary policy decision, as well as a key report on the state of the consumer.

The Street had been looking for those responses to last at least 10 months. With Mirati’s stock up more than 150% from March lows, there had been some concern that positive results may already be priced in.

For 49 of the 51 lung cancer patients, their cancer didn’t advance during the study. Trial participants had been previously treated with chemotherapy and most had also received an immunotherapy like Merck & Co.’s Keytruda. Of the 23 patients whose tumors shrank with adagrasib, 19 haven’t had their cancer progress, and are still getting treated.

“This is a positive result any way you look at it, especially if you compare it to current standard of care,” Charles Baum, Mirati’s chief executive officer, said in a phone call before the data were made public.

Biotechs Move Toward First U.S. Covid-19 Vaccinations by Yearend

  Biotechs Move Toward First U.S. Covid-19 Vaccinations by Yearend October is a critical month in the race for a Covid-19 vaccine, with developments that could lead to some Americans getting inoculated in the final days of 2020. © Bloomberg A lab technician uses a pipette dropper during the antigen quantification process of the coronavirus vaccine research at the Valneva SA laboratories in Vienna, Austria, on Thursday, Aug. 6, 2020. The U.K. has signed agreements to buy 90 million doses of vaccines in development by drugmakers including Pfizer Inc., BioNTech SE and Valneva SE, joining countries around the world racing to secure supplies of protection against Covid-19.

Closely Watched Mirati Reveals Results to Rival Amgen Drug . Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials.

Find the latest Mirati Therapeutics, Inc. (MRTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Mirati Therapeutics (MRTX) Source: Shutterstock This clinical stage biotech stock has a novel approach to treating cell growth and cell division using what are called KRAS inhibitors. This company is all about cancer drugs . And some of its drugs in the pipeline show best-in-class efficacy, outperforming KRAS inhibitors made by some of the biggest pharmaceutical companies on the planet.

chart: Mirati stock hit a record ahead of the results © Bloomberg Mirati stock hit a record ahead of the results

Both Mirati and Amgen’s medicines target a mutation on a gene called KRAS found in an estimated 13% of non-small cell lung tumors. These mutations are particularly hard to treat and patients with them have a poorer prognosis. Many on Wall Street are expecting both companies to get accelerated approval for these new drugs. For Mirati, sales of the drug could reach $2.3 billion by 2027, according to five analysts’ estimates compiled by Bloomberg.

Results for one lung cancer patient whose cancer had spread to their brain showed their tumors shrank and a brain lesion disappeared.

Adagrasib data in other tumor types were also presented on Sunday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, though the most promising results to date for these drugs has been seen in lung cancer. The medicine is also being tested in combination with other cancer drugs as well as in earlier lines of treatment.

Mirati plans to seek U.S. accelerated approval of the medicine as a second line of treatment for lung cancer in the latter half of 2021.

For more articles like this, please visit us at bloomberg.com

©2020 Bloomberg L.P.

Red-Hot Biotechs to Take Center Stage at Blood Disorder Meeting .
Artists continue to create, while maintaining social distance, during the global pandemic.

usr: 1
This is interesting!